updated 1/6/2011 7:17:01 AM ET 2011-01-06T12:17:01

DALLAS, Jan. 6, 2011 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring XOMA Ltd. (Nasdaq:XOMA). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at: www.microstockprofit.com/lp/XOMA

XOMA Ltd. (XOMA) is a biopharmaceutical company focused on the discovery, development and manufacture of novel antibody therapeutics for its own proprietary pipeline as well as through license and collaborative agreements with pharmaceutical and biotechnology companies, and under its contracts with the U.S. government. XOMA has an integrated product development platform, extending from preclinical science to development and manufacturing. The Company's technologies have contributed to the success of marketed antibody products, including LUCENTIS for wet age-related macular degeneration and CIMZIA for rheumatoid arthritis and Crohn's disease.

For only $19 a month, you can sign up for our real-time stock alert service. Click here to join now: http://www.pennystocklive.com/premium-membership/

In the report, the analyst notes:

"The Company has a premier antibody discovery and development platform that incorporates an unmatched collection of antibody phage display libraries and proprietary Human Engineering(TM), affinity maturation, Bacterial Cell Expression (BCE) and manufacturing technologies.

"XOMA recently inked a development and commercialization deal with French drug maker Les Laboratoires Servier for XOMA 052, XOMA's anti-inflammatory drug candidate in multiple indications. … Under the terms of the agreement, XOMA will receive about $35 million up front, up to $470 million in milestone payments, and royalties up to a mid-teens percentage rate."

To read the entire report visit: www.microstockprofit.com/lp/XOMA

See what investors are saying about XOMA at http://www.stockhideout.com

Get breaking news on XOMA at http://thestockmarketwatch.com/

MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit: http://www.microstockprofit.com

MicroStockProfit.com Disclosure

MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.

CONTACT: Brian Johnson
         info@microstockprofit.com
         1-888-307-2850

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved

Discuss:

Discussion comments

,

Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 3.79%
$30K home equity loan FICO 4.99%
$75K home equity loan FICO 4.69%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.83%
13.79%
Cash Back Cards 17.80%
17.78%
Rewards Cards 17.18%
17.17%
Source: Bankrate.com